Group 1 - The core viewpoint of the article highlights the performance of the Huatai-PineBridge Medical Services Flexible Allocation Mixed C Fund, which has shown significant returns in recent periods [1] - The fund's latest net value is 1.9690 yuan, with a weekly return of 0.66%, a three-month return of 24.86%, and a year-to-date return of 66.44% [1] - The fund was established on February 14, 2022, and as of June 30, 2025, it has a total scale of 1.069 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Pharmaceutical, Kelun Pharmaceutical, and Hai Si Ke, with the top ten holdings accounting for a total of 68.66% of the portfolio [1]

Group 1 - The core viewpoint of the article highlights the performance of the Huatai Fuhua Medical Service Flexible Allocation Mixed C Fund, which has shown significant returns in recent periods [1] - The fund's latest net value is 1.9560 yuan, with a weekly return of 3.06%, a three-month return of 34.90%, and a year-to-date return of 65.34% [1] - The fund was established on February 14, 2022, and as of June 30, 2025, it has a total scale of 1.069 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Pharmaceutical, Ke Lun Pharmaceutical, and Hai Si Ke, with a total holding proportion of 68.66% [1] - The fund manager is Zhang Wei, who oversees the investment strategy and portfolio management [1]

Group 1 - The core viewpoint of the article highlights the performance and holdings of the Huatai Fuhua Medical Service Flexible Allocation Mixed C Fund, which has shown significant returns since its inception [1] - The fund's latest net value is 1.8980 yuan, with a weekly return of -1.20%, a three-month return of 29.56%, and a year-to-date return of 60.44% [1] - The fund was established on February 14, 2022, and as of June 30, 2025, it has a total scale of 1.069 billion yuan [1] Group 2 - The top ten stock holdings of the fund include companies such as Heng Rui Pharmaceutical, Kelun Pharmaceutical, and Hai Si Ke, with a combined holding percentage of 68.66% [1] - The fund manager is Zhang Wei, who oversees the investment strategy and portfolio management [1]

截止2025年3月31日，汇添富医疗服务灵活配置混合C前十持仓占比合计64.17%，分别为：恒瑞医药 （10.23%）、科伦药业（9.09%）、百利天恒（8.94%）、海思科（8.27%）、信立泰（6.66%）、泽璟 制药-U（6.10%）、新诺威（4.69%）、荣昌生物（3.49%）、诺诚健华-U（3.35%）、微电生理 （3.35%）。 来源：金融界 据了解，汇添富医疗服务灵活配置混合C成立于2022年2月，基金规模3.46亿元，成立来累计收益 率-3.47%。从持有人结构来看，截至2024年末，汇添富医疗服务灵活配置混合C的基金机构持有2.50亿 份，占总份额的97.27%，个人投资者持有0.07亿份，占总份额的2.73%。 公开信息显示，现任基金经理张韡女士:中国。康奈尔大学生物医学硕士,曾任东方证券医药助理研究员, 汇添富基金医药研究员、高级医药研究员及医药行业研究组组长。2021年3月25日至今任汇添富健康生 活一年持有期混合型证券投资基金的基金经理。2021年9月29日至今任汇添富香港优势精选混合型证券 投资基金的基金经理。2022年10月21日至今任汇添富达欣灵活配置混合型证券投资基金的基金经 ...